B. Vig

发表

Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug

S. Badawy, A. Narang, A. Yamniuk, 2015, Pharmaceutical Research.

Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models

Aditya U. Vanarase, M. Hussain, B. Vig, 2015, The AAPS Journal.

Formulation, Process Development, and Scale-Up: Spray-Drying Amorphous Solid Dispersions for Insoluble Drugs

B. Vig, M. Morgen, 2017 .

Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.

B. Vig, P. Timmins, D. McNamara, 2017, Molecular pharmaceutics.

Peptide transporter substrate identification during permeability screening in drug discovery: Comparison of transfected MDCK-hPepT1 cells to caco-2 cells

B. Vig, S. Chong, P. Balimane, 2007, Archives of pharmacal research.

Expression Profile of Drug and Nutrient Absorption Related Genes in Madin-Darby Canine Kidney (MDCK) Cells Grown under Differentiation Conditions

B. Vig, Charles Tilford, D. Wall, 2012, Pharmaceutics.

Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum.

B. Vig, Ho-Chul Shin, G. Amidon, 2003, Biochemical and biophysical research communications.

Studies on the antimicrobial substances of sponges. VI. Structures of two antibacterial substances isolated from the marine sponge Dysidea herbacea.

B. Vig, G. M. Sharma, 1972 .

A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.

B. Vig, Ho-Chul Shin, G. Amidon, 2004, Molecular pharmaceutics.

Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs: strategies and side reactions.

B. Vig, T. F. Murray, J. V. Aldrich, 2003, Biopolymers.

Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.

B. Vig, Ho-Chul Shin, G. Amidon, 2006, Biological & pharmaceutical bulletin.

Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter.

B. Vig, G. Amidon, Xueqin Song, 2005, Journal of medicinal chemistry.

Proline Prodrug of Melphalan Targeted to Prolidase, a Prodrug Activating Enzyme Overexpressed in Melanoma

B. Vig, G. Amidon, Xueqin Song, 2007, Pharmaceutical Research.

Enhanced Absorption and Growth Inhibition with Amino Acid Monoester Prodrugs of Floxuridine by Targeting hPEPT1 Transporters

B. Vig, G. Amidon, C. Ramachandran, 2008, Molecules.

Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.

B. Vig, T. F. Murray, J. V. Aldrich, 2003, Journal of Medicinal Chemistry.

Amino acids as promoieties in prodrug design and development.

B. Vig, J. Rautio, K. Huttunen, 2013, Advanced drug delivery reviews.

Understanding Protein-Interface Interactions of a Fusion Protein at Silicone Oil-Water Interface Probed by Sum Frequency Generation Vibrational Spectroscopy.

Zhan Chen, Vishal Nashine, B. Vig, 2018, Journal of pharmaceutical sciences.

Cross linking of poly (vinyl alcohol) films under acidic and thermal stress.

Ravi P. Shah, S. Badawy, S. Varia, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.

B. Vig, G. Amidon, Xueqin Song, 2005, Molecular pharmaceutics.

Amino Acid Ester Prodrugs of Floxuridine: Synthesis and Effects of Structure, Stereochemistry, and Site of Esterification on the Rate of Hydrolysis

B. Vig, Ho-Chul Shin, G. Amidon, 2003, Pharmaceutical Research.

Amino acid prodrugs for oral delivery: challenges and opportunities.

B. Vig, J. Rautio, 2011, Therapeutic delivery.

Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs

B. Vig, G. Amidon, Xueqin Song, 2005, Molecular Cancer Therapeutics.

Gordon L. Amidon: Very Sustained Drug Absorption.

Lawrence X. Yu, J. Polli, B. Vig, 2015, Journal of pharmaceutical sciences.

PHENYLLITHIUM–PYRIDINE ADDUCT AS A REDUCING AGENT FOR KETONES

B. Vig, R. Abramovitch, 1963 .

Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models

Aditya U. Vanarase, M. Hussain, B. Vig, 2015, The AAPS Journal.

Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy.

D. Patel, K. Raghavan, B. Vig, 2013, Molecular pharmaceutics.

Application of imaging based tools for the characterisation of hollow spray dried amorphous dispersion particles.

Richard L. Schild, B. Vig, A. P. Ferreira, 2014, International journal of pharmaceutics.

Studies on the antimicrobial substances of sponges. IV. Structure of a bromine-containing compound from a marine sponge.

B. Vig, P. Burkholder, G. M. Sharma, 1970, The Journal of organic chemistry.

Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.

B. Vig, T. Stouch, D. Wall, 2006, Journal of medicinal chemistry.

A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.

B. Vig, G. Amidon, T. Stouch, 2004, Molecular pharmaceutics.

Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.

B. Vig, G. Amidon, Xueqin Song, 2005, Molecular pharmaceutics.

A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminus.

B. Vig, T. F. Murray, J. V. Aldrich, 2003, Journal of medicinal chemistry.